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Background: Several signal transduction pathways have been reported being involved in the acquisition of P-glycoprotein
(P-gp) mediated multi-drug resistance (MDR) upon exposure to anti-cancer drugs, whereas there is evidence indicating that
the expression and activity of P-gp were not equally or even reversely modulated by different drugs.
Methods: To further illustrate this drug-specific effect, possible mechanisms that enable breast cancer cells MCF-7 to acquire
MDR to either paclitaxel (PTX) or doxorubicin (DOX) were investigated in a time-dependent manner.
Results: The results suggested that at least two pathways participated in this process. One was the short and transient
activation of NF-κB, the second one was the relatively prolonged induction of PXR. Both PXR and NF-κB pathways took
part in the PTX drug resistance acquisition, whereas DOX did not exert a significant effect on the PXR-mediated induction
of P-gp. Furthermore, the property of NF-κB activation shared by DOX and PTX was not identical. An attempt made in
the present study demonstrated that the acquired resistance to DOX was via or partially via NF-κB activation but not its
upstream receptor TLR4, while PTX can induce the drug resistance via TLR4-NF-κB pathway.
Conclusions: To our knowledge, this report is among the first to directly compare the time dependence of NF-κB and PXR
pathways. The current study provides useful insight into the distinct ability of DOX and PTX to induce P-gp mediated MDR
in breast cancer. Different strategies may be required to circumvent MDR in the presence of different anti-cancer drugs.
Keywords: Multi-drug Resistance Acquisition (MDR), P-glycoprotein (P-gp), Drug-specific, Doxorubicin (DOX), Paclitaxel (PTX)Background
Chemotherapeutics are an effective treatment against tu-
mors. However, the efficacy of the treatment may be im-
peded by multi-drug resistance (MDR), a phenomenon
that consists in the development of resistance by the
tumor [1]. In the case of breast cancer, initially respon-
sive tumors frequently relapse and acquire resistance to
a broad spectrum of drugs after the initial sensitivity to
cytotoxic agents [2]. Among the recognized mechanisms
underlying the MDR, the efflux of the drugs by ATP
binding cassette (ABC) transporters in the membrane
compartments was the most concerned one [3]. Even
though this mechanism has not been unveiled com-
pletely, avoiding the appearance of drug resistance and
modulating the MDR have been a great challenge to
cancer therapy in clinic and laboratory.* Correspondence: ychen@njmu.edu.cn
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unless otherwise stated.Among the ABC transporters, P-glycoprotein (P-gp) is
the first described and most extensively studied one [4].
This transporter protein is encoded by the gene multi-drug
resistance 1 (MDR1) in human and is expressed widely in
epithelial cells of many organs [5]. Its expression can be al-
tered by a variety of xenobiotics, thus affecting its transport
activity [6]. As typically and commonly used cytotoxic
drugs in the treatment of breast cancer, paclitaxel (PTX, a
microtubule-stabilizing drug) and doxorubicin (DOX, a
DNA damaging drug) can both enhance the P-gp expres-
sion and induce MDR, resulting in the failure of chemo-
therapy [7]. However, cDNA microarray analysis provided
the evidence that isogenic PTX- and DOX-resistant breast
cancer cells indicated distinct drug-specific genetic signa-
tures of resistance that accompanied the establishment of
PTX or DOX resistance [8]. Differences in the capacity of
drugs to induce cross-resistance to each other have been
also reported for DOX and PTX [7]. The basis for this
drug-specific effect in the process of drug resistance acqui-
sition is so far unclear. Currently, of particular importanceis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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path-physiologically modulated.
To date, a number of studies have described that acti-
vation of nuclear factor-kappa B (NF-κB) leads to the al-
ternation of P-gp activity. However, the results of these
studies are inconclusive. Most of them suggested that
P-gp was up-regulated by NF-κB activation [9,10], while
others demonstrated a down-regulation effect [11]. In
addition to NF-κB, another inducer associated with the
P-gp expression and activity is pregnane X receptor
(PXR). As an orphan nuclear receptor known for its acti-
vation by structurally diverse compounds, PXR is impli-
cated as a novel regulator of MDR in cancers [12]. Even
though a variety of xenobiotics and endogenous ligands
have been reported as the activators of PXR and NF-κB
[13,14], whether PXR and NF-κB pathways cause the dif-
ference of resistance acquisition to DOX and PTX have
not been explored yet.
In this study, we investigated the impact of DOX and
PTX on the expression and transport activity of P-gp in
breast cancer cells MCF-7. The potential modulation of
drugs on the NF-κB and PXR-mediated P-gp induction
were evaluated. Since toll-like receptor 4 (TLR4) signal-
ing pathway generally culminates in the activation of
NF-κB [15], the role of TLR4 was also investigated. The
ultimate aim of this study is to provide further insight
into the P-gp mediated MDR acquisition and enhance




PTX was purchased from Hisun Pharmaceutical Co., Ltd.
(Zhejiang, China) and DOX was from Sigma-Aldrich (St.
Louis, MO, USA). Rhodamine 123 (Rho-123) and Bay
11–7082 were both supplied by Sigma-Aldrich (St. Louis,
MO, USA). Triton X-100 and phenylmethanesulfonyl fluor-
ide (PMSF) were from Generay Biotech Co., Ltd. (Shanghai,
China). Deoxycholate was from Biosharp (Huaibei, Anhui,
China). Penicillin was obtained from CSPC Zhongnuo
Pharmaceutical Co., Ltd (Shijiazhuang, China). Strepto-
mycin was obtained from Merro Pharmaceutical Co., Ltd
(Dalian, China).
Cell culture and drug treatment
Human breast cancer cell line MCF-7 was purchased
from ATCC (Rockville, MD, USA) and its correspond-
ing DOX-resistant cells (MCF-7/DOX) were obtained
from KeyGEN BioTech (Nanjing, China). PTX-resistant
cells (MCF-7/PTX) was generously donated by Dr. Sun
[16]. MCF-7/DOX cells were cultured in RPMI 1640
media (with L-glutamine and sodium pyruvate) supple-
mented with 10% fetal bovine serum (Thermo Scientific
Hyclone, Utah, USA) at 37°C and 5% CO2. MCF-7 andMCF-7/PTX cells were maintained routinely in DMEM
media supplemented with 10% fetal bovine serum, 100
U/mL penicillin and 100 μg/mL streptomycin.
Reverse transcriptase (RT)-PCR and real-time quantitative
RT-PCR (qRT-PCR)
Total RNA was isolated from cells using RNAiso Plus
reagent (Takara, Dalian, China) according to the manu-
facture’s instructions and quantified using UV absorb-
ance spectroscopy. For single-strand cDNA synthesis,
1 μg total RNA was reverse transcribed in a 10 μL reac-
tion using the 5 × primescript RT Master Mix (Takara,
Dalian, China) at 37°C for 15 min. The expression profiles
of MDR1 that encodes P-gp in MCF-7, MCF-7/DOX and
MCF-7/PTX cells were evaluated using RT-PCR with the
MJ Mini Personal Thermal Cycler (Bio-Rad Laboratories,
Richmond, USA). Details of primers and predicted band
sizes of PCR products are shown in Additional file 1:
Table S1. The amplified products were run on 3% Gel-red
(Biotium, CA, USA) stained agarose gel and visualized
under UV light.
qRT-PCR for PXR and MDR1 was done using an Ap-
plied Biosystems 7500 real-time PCR system (Applied
Biosystems, CA, USA). The total reaction volume was
20 μL containing 2 × SYBR Green PCR master mix
(Takara, Dalian, China), 200 nmol/L of each primer and
2 μL cDNA as template. After two initial steps of 50°C
for 2 min and 95°C for 6 min, the PCR reaction was run
40 cycles of 95°C for 15 s and 60°C for 1 min. Melt cure
analyses were done for all samples and only sharp melting
points were observed, indicating a specific signal and no
primer dimmers or mispriming. The Ct value is defined
as the fractional cycle number at which the fluorescence
passes the fixed threshold. Quantification of PXR and
MDR1 mRNA for each sample was calculated by correct-
ing for against the Ct level of GAPDH. The data are nor-
malized to controls (untreated cells) and presented as
mean data (± S.D.) of three different experiments.
Measurement of P-gp activity in MCF-7 Cells
P-gp activity in MCF-7 cells was assessed based on Rho-
123 uptake. Rho-123 is a typical substrate of P-gp, and a
decrease or increase in Rho-123 uptake by cells reflects
the enhancement or suppression of P-gp function, re-
spectively. Briefly, cells were seeded onto 6-well plates
and pretreated with drugs, then incubated with 2.5 μM
Rho-123 in the dark at 37°C for 60 min. After washed
twice with ice-cold PBS, cells were harvested in 400 μL
of 1% (v/v) Triton X-100 in PBS. Then, the whole cell lys-
ate was centrifuged at 13,000 rpm for 10 min at 4°C. The
amount of Rho-123 was determined using the 96-well
fluorescence plate reader with excitation/emission wave-
lengths at 510/536 nm using EnSpire 2300 (PerkinElmer,
Waltham, MA, USA). The total protein concentration was
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USA) according to the manufacturer’s protocol. The
amount of intracellular Rho-123 was normalized to the
total protein concentration. The ratio of these data in
the absence or presence of drugs/inhibitors is indicative
for the activity of P-gp. The data are presented as mean
data (± S.D.) of three different experiments. In this
study, the initially selected concentrations of PTX were
1, 2.5, 5, 10, 25, 50 nM and those of DOX were 10, 25,
50, 100, 250, 500 nM. Then, the cells were pretreated
with PTX and DOX at the concentrations having the
maximal effect.
Protein extraction and Western blotting
The cells were washed twice with ice-cold PBS and lysed
in RIPA lysis buffer (Beyotime, Shanghai, China). After
incubated on ice for 40 min, the whole cell lysate was
centrifuged at 12,000 rpm to remove cellular debris.
Cytosolic and nuclear proteins were isolated using the
NE-PER nuclear and cytoplasmic extraction kit (Pierce,
Rockford, USA) according to the manufacturer’s protocol.
50 μg of total protein was resolved by 4-12% SDS-PAGE,
unless stated otherwise, and transferred onto a polyvinyli-
denefluoride (PVDF) membrane (Millipore, Billerica, MA,
USA). Western blot analysis was performed using primary
antibodies for PXR (1:1000, Biolegend, CA, USA), NF-κB
p65 (1:500, Cell signaling, Beverly, MA, USA), P-gp (1:200,
Abcam, Cambridge, UK) GAPDH, Actin (1:2000, Bioworld,
Nanjing, China) and Anti-TATA binding protein (TBP)
antibody (1:500, Proteintech, Chicago, IL, USA), followed
by HRP-conjugated goat anti-mouse/rabbit IgG (1:5000,
MultiSciences Biotech. Co., Ltd., Hangzhou, China). The
proteins were then detected using enhanced chemilumin-
escence reagent (Pierce, Rockford, USA) according to the
manufacturer’s protocol.
Analysis of NF-κB p65 translocation using confocal
microscopy
MCF-7 cells were grown on confocal petri dish and
treated with two drugs for 24 h. Then, the cells were
washed with PBS, fixed with 4% paraformaldehyde and
permeabilized with PBST (0.2% Triton X-100 in PBS) so-
lution for the entrance of NF-κB p65 antibody. The cells
were blocked with 5% BSA in PBS, followed by the
rabbit monoclonal NF-κB p65 antibody (1:25, Cell sig-
naling, Beverly, USA) prepared in 3% BSA in PBS over-
night. After washing three times with PBS, Dylight 488
Affinipure goat anti-rabbit IgG (H + L) (1:200, EarthOx,
California, USA) secondary antibody was added and in-
cubated at room temperature for 1 h. Then DAPI stain
(10 μg/ml) for nuclei was added and images were ac-
quired at room temperature using a LSM700 confocal
microscope with a C-Apo × 40 water immersion lens
(Carl Zeiss, Germany).Cellular modulation of PXR expression with small
interfering RNA (siRNA)
The siRNA sequence targeting human PXR gene and the
negative control that consisted of a non-complementary
sequence were developed by GenePharma (Shanghai,
China). Three different sequences were evaluated first.
The PXR siRNA with the following sense and anti-sense
sequences was chosen: 5′-GAUGGACGCUCAGAUGAA
ATT-3′ (sense) and 5′-UUUCAUCUGAGCGUC- CAUC
TT-3′ (anti-sense). Cells were grown to approximately
80% confluence in 6-well plates and transfected with 20
pM PXR siRNA using Lipofectamine 2000 (Invitrogen,
Breda, Netherlands). The cells were incubated at 37°C
with 5% CO2 for subsequent analysis.
Inhibition of TLR4 and NF-κB pathways
BAY 11–7082, which can block the phosphorylation of
IκB and decrease the expression of adhesion molecules,
was used as an NF-κB inhibitor [17]. MCF-7 cells were
first grown in 6-well plates and incubated for 48 h, prior
to the incubation with 5 μM BAY 11–7082 for 2 h,
followed by PTX and DOX treatment. To measure the
function of TLR4, which is the upstream signal trans-
duction of NF-κB activation, TLR4 was blocked by a pre-
treatment with 2 μg of the anti-human TLR4-blocking
antibody (Hycult Biotech, Holland).
Data analysis
Mann–Whitney test was used to analyze the difference be-
tween two groups. Data were presented as mean ± S.D.
The general acceptance level of significance was p < 0.05.
Results
P-gp and MDR1 mRNA expression in cells
Three MCF-7 cell lines were first phenotyped for P-gp
expression using Western blotting. Consistent with pre-
vious studies [18,19], a well-defined band at approxi-
mately 170 kDa was detectable in MCF-7/DOX and
MCF-7/PTX cells compared to their parental MCF-7 cells
(Figure 1A and B). In addition, mRNA expression of P-
gp was determined. As expected, similar result was ob-
tained. MCF-7 cells expressed a low level of MDR1
mRNA, barely detectable using RT-PCR assay (Figure 1C).
Up-regulation of MDR1 mRNA was observed in drug-
resistant cells. Notably, the observed differences between
Western blotting and RT-PCR results were consistent with
the previous studies that the concordance between gene
and protein expression findings usually ranged from poor
to moderate [20]. Interestingly, both approaches indicated
a difference in the increase of P-gp level between MCF-7/
DOX and MCF-7/PTX cells. The enhancement of P-gp in
MCF-7/DOX cells was ~1.7 fold greater than that in
MCF-7/PTX cells.
Figure 1 Representative Western blotting (A) and quantitative analysis (B) of P-gp, PXR and NF-κB p65, and mRNA of MDR1 determined by
RT-PCR (C). GAPDH was used as the internal control.
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Both PXR and NF-κB are highly likely responsible for
the modulation of P-gp expression and activity. Thus,
the expression PXR and NF-κB p65 in MCF-7/PTX and
MCF-7/DOX cells were first conducted. Since activation
of NF-κB is associated with nuclear translocation of the
p65 component of the complex, quantification of nu-
clear p65 can be used as a parameter for NF-κB activa-
tion [21]. As shown in Figure 1A, MCF-7/DOX cells
have a higher enhancement of NF-κB/p65, even though
an increase was obtained in both MCF-7/DOX and
MCF-7/PTX cells. On the other hand, MCF-7/PTX cells
have a ~1.3-fold higher expression of PXR than itsparental MCF-7 cells, whereas the difference of this re-
ceptor between MCF-7/DOX and MCF-7 cells was not
easily distinguishable.
Impact of DOX and PTX on P-gp expression and activity
in short-term and long-term
To closely monitor the PXR and NF-κB changes in the
development of resistance to DOX and PTX, MCF-7
cells were induced by these drugs in a time course here.
The first step in the experimental design is the selection
of DOX and PTX concentration for the treatment of
cells. Thus, an investigation was performed to evaluate
the P-gp expression of MCF-7 cells as function of PTX
Figure 2 The impact of DOX and PTX on P-gp expression and activity. (A) The concentration-dependent effect of DOX and PTX on mRNA
level of MDR1. The cells were treated with drugs for 12 h. (B) The time-dependent effect of drugs on mRNA levels of MDR1 with 100 nM DOX/25
nM PTX treatment. (C) Rho-123 fluorescence ratio in MCF-7 cells with DOX and PTX treatments at different concentrations. (D) Rho-123
fluorescence ratio in MCF-7 cells with 100 nM DOX/25 nM PTX treatment for 0, 2, 4, 8, 12, 24, 36, 48 h. (E) MDR1 mRNA levels in MCF-7 cells
with 8 h/36 h DOX and PTX treatment. *, p < 0.05; **, p < 0.01 (n = 3). (F) Rho-123 fluorescence ratio in MCF-7 cells with 8 h/36 h DOX and PTX
treatment. *, p < 0.05 (n = 3).
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centrations of PTX were 1, 2.5, 5, 10, 25, 50 nM and
those of DOX were 10, 25, 50, 100, 250, 500 nM, follow-
ing their previously reported IC50 values [7]. The results
suggested that the maximal effect of drugs were ob-
served at DOX 100 nM and PTX 25 nM (Figure 2A
and C) with 12 h treatment time. Therefore, these con-
centrations were used in the following experiments.
The cells were subsequently analyzed for mRNA levels
of MDR1 after different drug treatment lengths. As a re-
sult, P-gp induction was an early event in the process of
drug resistance acquisition (Figure 2B). After a compari-
son at individual time points, we found that the increase
in the level of MDR1 mRNA after exposure to DOX and
PTX reached 2.39 and 2.01 folds at 8 h, suggesting a tran-
scriptional regulation of P-gp by these drugs (Figure 2E).
A higher enhancement was achieved by DOX. However,
this up-regulation was down-regulated following a more
prolonged exposure (e.g., 36 h) to PTX (1.82 fold),
whereas this alternation was not observed for DOX (1.17
fold, P > 0.05) (Figure 2E).
Meanwhile, P-gp transport activity was also analyzed.
We exposed the cells to the fluorescent P-gp substrate
Rho-123 and measured P-gp activity by comparing the
intracellular accumulation of Rho-123 [22,23]. The
concentration and time points were the same as those
used in the qRT-PCR assay (Figure 2C-D). In agree-
ment with protein level, intracellular Rho-123 signifi-
cantly decreased in 8 h after drug exposure (80.1% for
DOX and 87.5% for PTX), indicative of a declined P-gp
function (Figure 2F). In a long-term exposure, a similar
phenomenon to the mRNA result was also observed
that the function of P-gp was resumed in DOX not
PTX treated cells.
Activation of NF-κB pathway
NF-κB is a transcription factor that induces the expres-
sion of genes involved in many biological responses in-
cluding inflammation, cell proliferation and survival
[24]. The majority of NF-κB exists as a heterodimer of
p65/p50 proteins sequestered in the cytosol and bound
to inhibitory IκB proteins [25]. Stimulation of cells can
activate IκB kinases that phosphorylate IκB and result in
ubiquitination and proteosomal degradation of IκB.
Then the free p65/p50 complex enters the nucleus and
initiates transcription of downstream effector genes [24].
Thus, the appearance of p65 in the nuclear extracts of
cells can be a sign of NF-κB activation.
In terms of p65 translocation, Western blotting of cyto-
plasmic and nuclear p65 was performed. Actin and TBP
were used as the loading control of cytoplasmic and nu-
clear fractions, respectively. As a result, both DOX and
PTX enhanced the level of p65 in the nuclear region.
Time-dependent analysis of NF-κB translocation from 0to 8 h indicated a rapid translocation rate maximizing at
2 h (Figure 3A-B). In addition, a higher value was achieved
upon exposure to DOX than PTX (Figure 3C-D). Of note,
an apparent decline of p65 at time points longer than 2 h
after the treatment of PTX was observed, probably attrib-
uted to the restored nuclear export of p65.
Inhibition of NF-κB pathway
To further investigate the NF-κB pathway, we examined
the effect of Bay 11–7082 on P-gp expression and activity.
Bay 11–7082 is an inhibitor of IκBα phosphorylation,
thereby permitting IκBα to bind and inactivate NF-κB [17].
As shown in Figure 4A-B, both DOX and PTX displayed
significantly lower entry of nuclear p65 in the presence of
Bay 11–7082 at 2 h. The reduced mRNA expression and
activity of P-gp were also observed (Figure 4C-D). In
addition, P-gp returned to its baseline in DOX treated cells,
whereas it only partially recovered in PTX treated cells and
the P-gp induction was not completely abolished. Further-
more, inhibition of NF-κB by Bay 11–7082 at 36 h was not
significant for both DOX and PTX treatments. Neverthe-
less, the resumed value at 36 h with the incubation of PTX
was even greater than that at 8 h and of control, whereas
DOX did not show such a trend, implying that at least an-
other factor in addition to NF-κB participated in the P-gp
modulation in PTX treated cells.
NF-κB activation via TLR4
In the upstream signal transduction of NF-κB activation,
several signaling molecules can bind to their correspond-
ing receptors, leading to the NF-κB signaling cascade [26].
Among them, TLRs generally signal through a MyD88-
dependent manner, which involves the early activation of
NF-κB [27]. As the first TLR discovered in humans, to-
gether with that both DOX and PTX have been reported
as its potential ligands [28,29], TLR4 was examined in this
study. The involvement of TLR4 was investigated using
blocking antibody. The result indicated that PTX-induced
NF-κB activation and P-gp overexpression were inhibited
by anti-TLR4 antibody (Figure 5A-C). On the contrary,
there was no significant alternation in P-gp level of DOX
treated cells.
Finally, NF-κB pathway was also examined using con-
focal microscopy (Figure 6). The effects of anti-TLR4 anti-
body and Bay 11–7082 were demonstrated with Dylight
488 (green fluorescence) and DAPI (blue fluorescence) as
p65 and nuclear stains. The obtained results were consist-
ent with those of Western blotting. These data provided
alternative evidence of NF-κB pathway underlying the
drug resistance acquisition.
Activation of PXR pathway
Time-course study of PXR induction indicated that the
expression of PXR mRNA increased with the treatment
Figure 3 p65 translocation in MCF-7 cells after the treatment of DOX and PTX. (A) Western blotting and (B) nuclear:cytoplasmic ratio of
NF-κB p65 in cytoplasmic and nuclear fractions of DOX and PTX treated MCF-7 cells at 0, 0.5, 1, 2, 4, 8 h. (C) Western blotting of NF-κB p65 after
2 h treatment of DOX and PTX using Actin and TBP as loading controls. (D) A quantitative analysis of nuclear:cytoplasmic ratio of p65 in (C). *, p
< 0.05; **, p < 0.01; ***, p < 0.001 (n = 3).
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plateau over 24 h later (Figure 7A). Correspondingly,
PXR protein level enhanced in accordance with the ob-
served level of mRNA (Figure 7B). On the contrary to
PTX, DOX can not cause PXR change at both protein
and mRNA levels.
To further examine whether the induction of DOX
and PTX on P-gp was via the PXR activation, we de-
signed a small interfering RNA targeting PXR to knock-
down its expression. As a result, silencing efficiency of
80% was achieved compared with that of the non-
targeting siRNA (Figure 7C). Neither mock (absence ofsiRNA) nor non-targeting siRNA had any effect on PXR
mRNA levels. Then these silenced cells were used for
PTX and DOX treatment and the result is shown in
Figure 7D. While control cells (mock) exhibited an ex-
tent of P-gp induction by PTX, the siRNA-mediated
PXR knock-down cells have an alleviated increase of P-
gp in both expression and activity at 36 h (p < 0.01),
strongly suggesting that this nuclear receptor was indeed
implicated in the regulation of MDR1 gene. In contrast
to PTX, DOX did not show such a result. There was no
significant difference (p > 0.05) between the mock and
siRNA transfected cells. Most importantly, relatively
Figure 4 Effect of NF-κB inhibitor Bay 11-7082 in DOX and PTX treated cells. (A-B) Effect of Bay 11–7082 on the expression of NF-κB p65 in
cytoplasmic and nuclear fractions with 8 h treatment of DOX and PTX and Bay 11–7082 for 2 h. (C) Relative MDR1 mRNA of DOX and PTX treated
cells. *, p < 0.05; **, p < 0.01, blank P > 0.05 (n = 3). (D) Rho-123 fluorescence ratio of DOX and PTX treated cells. *, p < 0.05; **, p < 0.01, blank,
P > 0.05 (n = 3).
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cific, siRNA transfected cells had a significant decline of
P-gp level at 36 h, but not at 8 h.
Discussion
As earlier mentioned, DOX and PTX are used to treat
breast cancer via distinct mechanisms [30]. The mechanism
of DOX action is topoisomerase II inhibition and free rad-
ical generation. On the other hand, the effect of paclitaxel is
related to its ability to bind to tubulin, to promote micro-
tubule assembly, and to stabilize microtubules by bundle
formation. In addition to this difference, there are several
studies indicating that their ability to induce drug resistance
is agent-specific [7,8]. However, few investigations provide
significant insight into possible signal transduction path-
ways that enable breast cancer cells to acquire resistance to
either PTX or DOX. In this study, MDR1 mRNA and Rho-
123 assay were used to monitor the expression and activity
of P-gp. The time-dependent result indicated that drug re-
sistance induced upon exposure to PTX reserved after
reaching the peak value, different from an apparent declineobserved in DOX treated cells. This difference may be at-
tributed to distinct ability of DOX and PTX to induce P-gp
expression. It is reasonable to assume that multiple at least
two pathways participated in the modulation of P-gp ex-
pression and function. One is short-term; the second one is
relatively long-term.
There are several possible mechanisms underlying P-gp
modulation disclosed over the past several years [31,32].
Among them, one potential intracellular target is NF-κB.
As reported previously, both PTX and DOX shared the
property of NF-κB activation [30]. Since transcription of
IκBα is positively autoregulated by NF-κB, activation of
NF-κB is usually self-terminated within minutes to hours,
appearing short and transient [33,34]. In this study, the
appearance of p65 at early time points (i.e., 2 h) and the
incompetence of NF-κB inhibitor at a late time point (i.e.,
36 h) were consistent with its rapid nature in in vitro stud-
ies [34]. Furthermore, the partially restored level of P-gp
at 8 h and its enhanced level at 36 h in PTX treated cells
in the presence of NF-κB inhibitor confirmed that the im-
pact of NF-κB pathway was less significant on the
Figure 5 Effect of anti-TLR4 antibody. (A-B) Western blotting and quantitative analysis of nuclear and cytoplasmic p65 after the use of TLR4-
blocking antibody. (C) Relative MDR1 mRNA level and Rho-123 fluorescence ratio of DOX and PTX treated cells. *, p < 0.05; **, p < 0.01, blank,
p > 0.05 (n = 3).
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at least one more pathway took part in the PTX drug
resistance acquisition than that of DOX.
PXR has been identified as another major regulator of
P-gp induction [12,35]. Of the 170 xenobiotics tested,
54% of them demonstrated some level of PXR transacti-
vation [13]. PTX was one of them. Different from PTX,
DOX did not exert a significant effect on both PXR acti-
vation and the PXR-mediated induction of proteins, for
example P450 3A4 (CYP3A4) [36]. Our results were
in agreement with these findings, indicating that PTX
but not DOX activated PXR-mediated P-gp induction
and affected the expression and activity of P-gp. Com-
pared to short-term activation of NF-κB signaling, the
activation of PXR on P-gp seemed relatively long-term.
The induction of PXR culminated at the time points
(i.e., 24 h) longer than that of NF-κB and was then per-
sistent at a stable level in our experimental period (i.e.,
24–36 h). Similarly, the protein level of P-gp in PXR
siRNA-transfected cells was more influenced at late time
points with the treatment of PTX. Although this chronic
effect has been previously reported in vivo [37,38], the
direct comparison of the time dependence of NF-κB andPXR activation was firstly performed in this study. Not-
ably, the combined data of these two pathways greatly
matched the alternation trend of P-gp at protein and
mRNA levels.
Despite of NF-κB and PXR signaling pathways investi-
gated here, several issues observed in the experiments
remained inclusive. For example, P-gp level was not
equally induced by DOX and PTX via NF-κB activation.
DOX treated cells obtained a higher P-gp expression
and activity, which may lead to the ultimate higher P-gp
level in MCF-7/DOX cultured cells. Unfortunately, the
precise mechanisms that allow drugs to induce NF-κB
activation have not been fully illustrated [39]. Since both
DOX and PTX are potential ligands of TLR4 in the up-
stream signal transduction of NF-κB, we hypothesized
here that TLR4 may be involved in the up-regulation of
P-gp expression via NF-κB. The results indicated that
there was a possibility that the acquired resistance to
DOX was via or partially via NF-κB activation but not
TLR4. PTX can induce the drug resistance via TLR4-
NF-κB pathway.
It deserves to mention that TLR4 is not the single recep-
tor upstream the NF-κB pathway. It was selected here
Figure 6 Confocal images of p65 in cells after the treatment of DOX (A) and PTX (B) with or without Bay 11–7082 inhibition and TLR4
antibody blocking. Cells were stained with Dylight 488 (green fluorescence) for p65 and co-stained with DAPI (blue) for positive identification of
nuclei. The cells (arrow) are also enlarged at single-cell level for clarification (right images).
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and PTX. In addition to TLR4, NF-κB can also be acti-
vated by other receptors, such as IL-1R, TNF-R and other
TLRs [26]. These upstream signaling components are also
receptor-specific. Furthermore, the target gene products
of NF-κB include many cytokines, chemokines and cell ad-
hesion molecules [13]. Previous studies have shown that
these products can be inducers of P-gp under several
pathological conditions, such as infection, tumor, and dia-
betes mellitus [14-16]. For instance, DOX can inhibit the
transcriptional activation of the oxidative stress-responsive
heat shock factor 1 (HSF-1) and the subsequence declined
expression of heat shock proteins in turn reverse the drug
resistance by inhibiting MDR1/P-gp expression [40]. Such
findings may be employed to explain drug resistanceacquired upon exposure to DOX. Therefore, further stud-
ies will be required to address these issues.
Finally, we like to point out that the association between
NF-κB and PXR signaling pathways was not explored in
this study. In fact, recent studies revealed that a possible
functional link may exist between them [41]. For instance,
NF-κB/p65 can disrupt the connection of the PXR-RXRα
complex with DNA sequences [42]. On the other hand,
activated PXR was able to reduce the activity of NF-κB
[43]. Thus, their mutual inhibitory potential deserves fur-
ther assessment in the future.
Therefore, this study illustrated the differential drug
resistance acquisition to DOX and PTX in MCF-7 cells
by exploring NF-κB and PXR pathways. Recognition of
this difference could help us to provide better treatment
Figure 7 Impact of PXR activation in DOX and PTX treated cells. (A) PXR mRNA expression with the treatment of DOX and PTX at 0, 4, 8, 12, 24,
36, 48 h. (B)Western blot analysis of PXR with 24 h treatment of DOX and PTX. **, p < 0.01 (n = 3). (C) RT-PCR analysis of PXR mRNA in PTX only (PTX)
or treated cells exposed to transfection conditions in the absence of siRNA (mock) or cells transfected with non-targeting (NC) or PXR-specific siRNA
(siRNA). (D) Comparison of MDR1 mRNA expression in the cells exposed to transfection conditions with 8 h/36 h DOX and PTX treatment. **, p < 0.01
(n = 3). (E) Rho-123 fluorescence ratio in the cells exposed to transfection conditions with 8 h/36 h DOX and PTX treatment. *, p < 0.05 (n = 3).
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tential signaling components and interactions, more in-
vestigation is in demand.
Conclusions
To our knowledge, this report is among the first to dir-
ectly compare the time dependence of NF-κB and PXR
pathways. Differential drug resistance acquisition to
DOX and PTX in breast cancer MCF-7 cells was
depicted. As a short-term activation, NF-κB participated
in both DOX and PTX induction of P-gp. On thecontrary, PXR pathway is a relatively prolonged activa-
tion and only PTX has an effect on the PXR-mediated
induction of P-gp. This study provides significant insight
into the possible pathways through which resistance to
agents may be acquired in breast cancer. However, it de-
serves to point out that a wide variety of signaling path-
ways are involved in P-gp mediated MDR in addition to
NF-κB and PXR, including mitogen-activated protein
kinase (MAPK), c-Jun NH2-terminal kinase (JNK), p38,
cyclic adenosine monophosphate-dependent protein kin-
ase, phosphatidylinositol 3-kinase and protein kinase C
Xu et al. Cancer Cell International 2014, 14:142 Page 12 of 13
http://www.cancerci.com/content/14/1/142[44]. Additional studies about these pathways will be re-
quired to better understand the drug acquisition process
and provide strategies to circumvent MDR.
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